Atherosclerosis Drugs Market Size Projected To Increase From $52.44 Billion To $61.19 Billion During The Forecast Period
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Atherosclerosis Drugs Market Growth From $52.44 Billion In 2026 To $61.19 Billion By 2030 At A CAGR Of 3.9%
The market for atherosclerosis medications has experienced consistent expansion in recent times. Projections indicate an increase from $50.91 billion in 2025 to $52.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.0%. This historical growth has been driven by factors such as the growing incidence of cardiovascular conditions, heightened public awareness regarding heart wellness, widespread use of statins and other cholesterol-reducing agents, governmental efforts focused on cardiovascular treatment, and the development of hospital and retail pharmacy networks.
The market for atherosclerosis medications is projected to experience consistent expansion over the coming years. By 2030, its valuation is anticipated to reach $61.19 billion, reflecting a compound annual growth rate (CAGR) of 3.9%. Several factors are fueling this growth during the forecast period, including the broader application of precision medicine in cardiovascular care, the growing use of digital health monitoring devices, an increasing preference for combination treatment approaches, a rising elderly population, and ongoing breakthroughs in novel anti-atherosclerosis drug categories. Key trends shaping the market include the shift toward personalized atherosclerosis therapies, the development of multi-drug formulations, the integration of minimally invasive treatment options, a greater emphasis on preventive heart health, and enhanced patient adherence supported by digital monitoring tools.
Download A Free Sample Report For Comprehensive Market Insights:
Atherosclerosis Drugs Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising occurrence of cardiovascular conditions is anticipated to accelerate the expansion of the atherosclerosis drug market in the coming years. Cardiovascular diseases encompass all disorders affecting the heart and blood vessels, while atherosclerosis specifically involves the accumulation of fats, cholesterol, and other materials on the arterial walls. This condition, marked by plaque buildup inside the arteries, leads to serious cardiovascular issues such as coronary heart disease and stroke. Medications for atherosclerosis are employed to address cardiovascular diseases by minimizing complication risks and managing underlying problems like elevated cholesterol levels and blood clot formation. As an example, in January 2024, the American Heart Association, a nonprofit organization based in the United States, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, representing a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the high prevalence of cardiovascular diseases is expected to be a key driver for the atherosclerosis drug market.
Atherosclerosis Drugs Market Segment Performance And Strategic Opportunities
The atherosclerosis drugs market covered in this report is segmented –
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
Atherosclerosis Drugs Market Innovation Trends Driving Future Development
Major players in the atherosclerosis drug market are focusing on the development of innovative products, particularly anti-inflammatory medications, to enhance their profitability in this sector. Atherosclerosis anti-inflammatory drugs are pharmaceutical agents intended to reduce inflammation linked to atherosclerosis, a disease marked by arterial plaque accumulation. In June 2023, AGEPHA Pharma, a European medical products firm, introduced LODOCO. LODOCO (colchicine, 0.5 mg tablet) received U.S. FDA approval as the first anti-inflammatory atheroprotective cardiovascular treatment. This drug has shown effectiveness in decreasing the incidence of myocardial infarction, stroke, coronary revascularization, and cardiovascular death among adults suffering from atherosclerotic disease or presenting multiple cardiovascular risk factors. By targeting residual inflammation, which plays a significant role in atherosclerotic cardiovascular disease (ASCVD), LODOCO represents a major advancement in cardiac care. It is approved for use as a standalone therapy or in combination with cholesterol-lowering agents.
Atherosclerosis Drugs Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.
Access The Complete Atherosclerosis Drugs Market Report:
Atherosclerosis Drugs Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
